Related Experiment Video

Updated: Apr 14, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.7K

Immune profiling in residual disease: refining risk stratification after neoadjuvant therapy in HER2-positive breast

Marcelo Antonini1,2, André Mattar2, Francisco Pimentel Cavalcante2

  • 1Department of Mastology, Hospital do Servidor Público Estadual, São Paulo, Brazil.

Translational Cancer Research
|April 13, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Human epidermal growth factor receptor 2-positive breast cancer (HER2-positive breast cancer)immune gene signaturesneoadjuvant therapyprognostic biomarkersresidual disease (RD)

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.3K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

876

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69